comparemela.com

Latest Breaking News On - Chansu vascular technologies - Page 1 : comparemela.com

Cardiovascular Systems (CSII) Q4 2022 Earnings Call Transcript

Cardiovascular Systems (NASDAQ:CSII) & Integrity Applications (NASDAQ:IGAP) Critical Contrast

Integrity Applications (NASDAQ:IGAP – Get Rating) and Cardiovascular Systems (NASDAQ:CSII – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider & Institutional Ownership 93.6% of Cardiovascular Systems shares […]

Cardiovascular Systems Inc (CSII) Q3 2021 Earnings Call Transcript

Cardiovascular Systems Inc (CSII) Q3 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Cardiovascular Systems Inc (NASDAQ: CSII) Popular Searches Operator Good day, and thank you for standing by. Welcome to Cardiovascular Systems, Inc. Fiscal Year 2021 Third Quarter Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Jack Nielsen, Vice President, Investor Relations. Please go ahead.SPONSORED: 10 stocks we like better than Cardiovascular Systems When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,

Cardiovascular Systems, Inc Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology

Press release content from Business Wire. The AP news staff was not involved in its creation. Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology February 1, 2021 GMT ST. PAUL, Minn. (BUSINESS WIRE) Feb 1, 2021 Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer in the successful development of several drug-coated devices. DCBs are a widely accepted percutaneous interventional treatment option for femoro-popliteal lesions in patients with peripheral artery disease (PAD), and are increasingly recognized for their potential in complex coronary artery disease (CAD), including their use in in-stent resteno

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.